Louisiana Laws - Louisiana State Legislature (2023)

§964. Composition of schedules

Schedules I, II, III, IV, and V shall, unless and until added to pursuant to R.S. 40:962,consist of the following drugs or other substances, by whatever official name, common orusual name, chemical name, or brand name designated:

SCHEDULE I

A. Opiates. Unless specifically excepted or unless listed in another schedule, anyof the following opiates, including their isomers, esters, ethers, salts, or salts of isomers,esters, and ethers, whenever the existence of such isomers, esters, ethers, or salts is possiblewithin the specific chemical designation:

*(1)Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide)

*(2) Acetylmethadol

*(3) Acrylfentanyl (N-[1-(2-phenylethyl)piperidin-4-yl]-N-phenylacrylamide)

*(4) Allylprodine

*(5) Alphacetylmethadol (except levo-alphacetylmethadol, also known aslevomethadyl acetate, or LAAM)

*(6) Alphameprodine

*(7) Alphamethadol

*(8) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl) ethyl-4-piperidyl]propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine)

*(9) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide)

*(10) Benzethidine

*(11) Betacetylmethadol

*(12) Beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide)

*(13) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide)

(14) Beta-hydroxythiofentanyl (N-[1-[2-hydroxy-2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenylpropanamide)

*(15) Betameprodine

*(16) Betamethadol

(17) beta-methylfentanyl (N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)propanamide)

(18) beta-phenylfentanyl (N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide)

*(19) Betaprodine

(20) Brorphine (1-(1-(1-(4-bromophenyl) ethyl) piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one)

(21) Butonitazene (N,N-diethyl-2-[(4-butoxyphenyl)methyl]-5-nitro-1H-benzimidazole-1-ethanamine)

(22) Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide)

*(23) Clonitazene

(24) Crotonyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide)

(25) Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide)

*(26) Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-y1)-N-phenylcyclopropanecarboxamide)

*(27) Dextromoramide

*(28) Diampromide

*(29) 3,4-Dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]-benzamide (AH-7921)

*(30) Diethylthiambutene

*(31) Difenoxin

*(32) Dimenoxadol

*(33) Dimepheptanol

*(34) Dimethylthiambutene

*(35) Dioxaphetyl butyrate

*(36) Dipipanone

*(37) Ethylmethylthiambutene

(38) Etodesnitazene (N,N-diethyl-2-[(4-ethoxyphenyl)methyl]-1H-

benzimidazole-1-ethanamine)

*(39) Etonitazene

*(40) Etoxeridine

(41) Fentanyl carbamate (ethyl(1-phenethylpiperidin-4-yl)(phenyl) carbamate)

(42) Flunitazene (N,N-diethyl-2-(4-fluorophenyl)methyl]-5-nitro-1H-benzimidazole-1-ethanamine)

(43) 4-Fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide)

(44) 2-fluoro-orthofluorofentanyl (N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl)propanamide)

*(45) Furanylfentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide)

*(46) Furethidine

*(47) Hydroxypethidine

(48) Isobutyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide)

(49) Isotonitazene (N,N-diethyl-2-[(4-isopropoxyphenyl)methyl]-5-nitro-1H-benzimidazole-1-ethanamine)

*(50) Ketobemidone

*(51) Levomoramide

*(52) Levophenacylmorphan

(53) Methoxyacetylfentanyl (2-methoxy-N-[1-(2-phenylethyl)piperidin-4-yl]-N-phenylacetamide)

(54) 4-methylacetylfentanyl (N-(1-(4-methylphenethyl)piperidin-4-yl)-N-phenylacetamide

*(55) 3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide)

*(56) 3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide)

(57) Metodesnitazene (N,N-diethyl-2-[(4-methoxyphenyl)methyl]-1H-

benzimidazole-1-ethanamine)

(58) Metonitazene (N,N-diethyl-2-[(4-methoxyphenyl)methyl]-5-nitro-1H-benzimidazole-1-ethanamine)

*(59) Morpheridine

*(60) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine)

(61) MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine)

(62) (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide) (acetyl fentanyl)

(63) N-pyrrolidino etonitazene (2-[(4-ethoxyphenyl)methyl]-5-nitro-1-

[2-(pyrrolidino-1-yl)ethyl]-1H-benzimidazole)

*(64) Noracymethadol

*(65) Norlevorphanol

*(66) Normethadone

*(67) Norpipanone

(68) Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide)

(69) Orthofluoroacrylfentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)acrylamide)

(70) Orthomethylacetylfentanyl (N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide)

(71) Orthomethylmethoxyacetylfentanyl (2-methoxy-N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide)

(72) Para-chloroisobutyryl fentanyl (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide)

(73) Para-fluorobutyrylfentanyl (N-(4-fluorophenyl)-N-[1-(2-phenylethyl) piperidin-4-yl]butanamide)

*(74) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl]propanamide)

(75) para-fluorofuranylfentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide)

(76) Para-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide)

(77) para-methylfentanyl (N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)propanamide)

*(78) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperdine)

*(79) Phenadoxone

*(80) Phenampromide

*(81) Phenomorphan

*(82) Phenoperidine

(83) Phenylfentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide)

*(84) Piritramide

*(85) Proheptazine

*(86) Properidine

*(87) Propiram

(88) Protonitazene (N,N-diethyl-2-[(4-propoxyphenyl)methyl]-5-nitro-1H-benzimidazole-1-ethanamine)

*(89) Racemoramide

(90) Tetrahydrofuranylfentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]tetrahydrofuran-2-carboxamide)

*(91) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide)

(92) Thiofuranylfentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylthiophene

-2-carboxamide)

*(93) Tilidine

*(94) Trimeperidine

*(95) U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide)

(96) U-48800 (2,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methyl-benzeneacetamide)

(97) U-49900 (3,4-dichloro-N-[2-(diethylamino)cyclohexyl]-N-methyl-benzamide)

(98) U-51754 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methyl-benzeneacetamide)

(99) Valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide)

B. Opium derivatives. Unless specifically excepted or unless listed in anotherschedule, any of the following opium derivatives, its salts, isomers, and salts of isomerswhenever the existence of such salts, isomers, and salts of isomers is possible within thespecific chemical designation:

*(1) Acetorphine

*(2) Acetyldihydrocodeine

*(3) Benzylmorphine

*(4) Codeine methylbromide

*(5) Codeine-N-Oxide

*(6) Cyprenorphine

*(7) Desomorphine

*(8) Dihydromorphine

*(9) Drotebanol

*(10) Etorphine, except hydrochloride salt

*(11) Heroin

*(12) Hydromorphinol

*(13) Methyldesorphine

*(14) Methyldihydromorphine

*(15) Morphine methylbromide

*(16) Morphine methylsulfonate

*(17) Morphine-N-Oxide

*(18) Myrophine

*(19) Nicocodeine

*(20) Nicomorphine

*(21) Normorphine

*(22) Pholcodine

*(23) Thebacon

C. Hallucinogenic substances. Unless specifically excepted or unless listed inanother schedule, any material, compound, mixture, or preparation, which contains anyquantity of the following hallucinogenic substances, or which contains any of their salts,isomers, or salts of isomers, whenever the existence of such salts, isomers, or salts of isomersis possible within the specific chemical designation, for purposes of this Subsection only, theterm "isomer" includes the optical, position, and geometric isomers:

(1) Alpha-ethyltryptamine

(2) Alphamethyltryptamine

(3) 5-(2-aminopropyl)-2,3-dihydrobenzofuran (5-APDB)

(4) 6-(2-aminopropyl)-2,3-dihydrobenzofuran (6-APDB)

(5) 5-(2-aminopropyl)benzofuran (5-APB)

(6) 6-(2-aminopropyl)benzofuran (6-APB)

(7) 4-bromo-2,5-dimethoxyamphetamine

(8) 4-bromo-2,5-dimethoxyphenethylamine

(9) 4-bromo-2,5-dimethoxyphenethylamine (2C-B)

(10) Bufotenine

(11) Deschloroketamine (2-phenyl-2(methylamino) cyclohexanone)

(12) Deschloro-N-ethyl-ketamine (2-(ethylamino)-2-phenylcyclohexan-1-one)

(13) Diethyltryptamine

(14) Diisopropyltryptamine (DIPT)

(15) 2,5-dimethoxy-4-chlorophenethylamine (2C-C)

(16) 2,5-dimethoxy-4-ethylamphetamine

(17) 2,5-dimethoxy-4-ethylphenethylamine (2C-E)

(18) 2,5-dimethoxy-4-ethylthiophenethylamine (2C-T-2)

(19) 2,5-dimethoxy-4-iodophenethylamine (2C-I)

(20) 2,5-dimethoxy-4-isopropylthiophenethylamine (2C-T-4)

(21) 2,5-dimethoxy-4-methylphenethylamine (2C-D)

(22) 2,5-dimethoxy-4-methylthiophenethylamine (2C-T)

(23) 2,5-dimethoxy-4-nitrophenethylamine (2C-N)

(24) 2,5-dimethoxy-4-(n)-propylphenethylamine (2C-P)

(25) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7)

(26) 2,5-dimethoxyamphetamine

(27) 2,5-dimethoxyphenethylamine (2C-H)

(28) Dimethyltryptamine

(29) Ethylamine analog of phencyclidine

(30) 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexanone (Methoxetamine)

(31) 4-Fluoroamphetamine (4-FA)

(32) 4-Fluoromethamphetamine (4-FMA)

(33) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DIPT)

(34) 4-hydroxy-N-methyl-N-isopropyltryptamine (4-Hydroxy-MIPT)

(35) Ibogaine

(36) 5-iodo-2-aminoindane (5-IAI)

(37) Lysergic acid diethylamide

(38) Marihuana

(39) Mescaline

(40) 4-methoxyamphetamine

(41) 5-methoxy-3,4-methylenedioxyamphetamine

(42) 5-methoxy-N,N-diallyl-tryptamine (5-MEO-DALT)

(43) 5-methoxy-N, N-diisopropyltryptamine

(44) 5-methoxy-N,N-dimethyltryptamine (5-MEO-DMT)

(45) 5-methoxy-N-methyl-N-isopropyltryptamine (5-MEO-MIPT)

(46) 4-methyl-2,5-dimethoxyamphetamine

(47) 5-(2-methylaminopropyl)benzofuran (5-MAPB)

(48) 5,6-methylenedioxy-2-aminoindane (MDAI)

(49) 3,4-methylenedioxyamphetamine

(50) 3,4-methylenedioxymethamphetamine (MDMA)

(51) 3,4-methylenedioxy-N-ethylamphetamine

(52) N-ethyl-3-piperidyl benzilate

(53) N-hydroxy-3,4-methylenedioxyamphetamine

(54) N-(2-hydroxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (25I-NBOH)

(55) N-(2-methoxybenzyl)-2,5-dimethoxy-4-bromophenethylamine (25B-NBOMe)

(56) N-(2-methoxybenzyl)-2,5-dimethoxy-4-chlorophenethylamine (25C-NBOMe)

(57) N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (25I-NBOMe)

(58) N-methyl-3-piperidyl benzilate

(59) Parahexyl, also known as Synhexyl

(60) para-methoxymethamphetamine (PMMA)

(61) Peyote

(62) Psilocybin

(63) Psilocyn

(64) Pyrrolidine analog of phencyclidine

(65) Tetrahydrocannabinols, including synthetic equivalents and derivatives, exceptfor tetrahydrocannabinols in hemp

(66) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine

(67) Thiophene analog of phencyclidine

(68) 3,4,5-trimethoxy amphetamine

D. Depressants. Unless specifically excepted or unless listed in another schedule,any material, compound, mixture, or preparation which contains any quantity of thefollowing substances having a depressant effect on the central nervous system, including itssalts, isomers, and salts of isomers whenever the existence of such salts, isomers, and saltsof isomers is possible within the specific chemical designation:

(1) Clonazolam

(2) Etizolam

(3) Flualprazolam

(4) Gamma-hydroxybutyric acid (GHB)

(5) Mecloqualone

(6) Methaqualone

(7) Phenazepam

E. Stimulants. Unless specifically excepted, or contained within a pharmaceuticalproduct approved by the United States Food and Drug Administration, or unless listed inanother schedule, any material, compound, mixture, or preparation which contains anyquantity of the following substances having a stimulant effect on the central nervous systemincluding its salts, isomers, esters, or ethers and salts of isomers, esters, or ethers wheneverthe existence of such salts, isomers, esters, or ethers and salts of isomers, esters, or ethers ispossible within the specific chemical designation:

(1) 2-amino-1-phenyl-1-propanone (cathinone) or variation in any of the followingways:

(i) By substitution in the phenyl ring to any extent with alkyl, hydroxyl alkoxy,alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted in thephenyl ring by one or more other univalent substituents.

(ii) By substitution at the 3-position with an alkyl substituent.

(iii) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, ormethoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure.

(2) Aminorex

(3) Cathinone

(4) 4,4-dimethylaminorex (4,4-DMAR)

(5) Fenethylline

(6) Methcathinone

(7) (+)cis-4-methylaminorex

(8) Naphthylpyrovalerone whether or not further substituted in the naphthyl ring toany extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or notfurther substituted in the naphthyl ring by one or more other univalent substituents orwhether or not further substituted in the carbon chain at the 3, 4, or 5 position with an alkylsubstituent.

(9) N-Benzylpiperazine (BZP)

(10) N-ethylamphetamine

(11) N,N-dimethylamphetamine

(12) 2-(pyrrolidin-1-yl)-1-(thiophen-2-yl)butan-1-one (Alpha-PBT)

(13) 2-(pyrrolidin-1-yl)-1-(thiophen-2-yl)pentan-1-one (Alpha-PVT)

F. Synthetic cannabinoids. Unless specifically excepted, or contained within apharmaceutical product approved by the United States Food and Drug Administration, orunless listed in another schedule, any material, compound, mixture, or preparation whichcontains any quantity of a synthetic cannabinoid found to be in any of the followingindividual compounds or chemical groups, or any of those individual compounds or groupswhich contain any synthetic cannabinoid salts, isomers, salts of isomers, or nitrogen-heterocyclic analogs, whenever the existence of such salts, isomers, salts of isomers, ornitrogen-heterocyclic analogs is possible within the specific compounds or chemical groups:

(1) Adamantoylindoles: any compound containing a 3-(1-adamantoyl)indolestructure, whether or not further substituted in the indole ring to any extent or whether or notsubstituted in the adamantyl ring to any extent.

(2) Adamantylamidoindoles: Any compound containing a N-(adamantyl)-1H-indole-3-carboxamide structure, whether or not further substituted in the indole ring to anyextent or whether or not substituted in the adamantyl ring to any extent.

(3) Benzoylindoles: any compound containing a 3-(benzoyl)indole structure,whether or not substituted in the indole ring to any extent or the phenyl ring to any extent.

(4) Benzylindolecarboxamides: Any compound containing aN-benzyl-1H-indole-3-carboxamide structure, whether or not further substituted in the indolering or the phenyl ring to any extent.

(5) Butaldehydeamidoindoles: Any compound containing aN-(1-oxobutan-2yl)-1H-indole-3-carboxamide structure, with or without substitution in theindole ring by an alkyl, haloalkyl, cyanoalkyl, alkoxy, aryl, aryl halide, alkylarylhalide,cycloalkymethyl, cycloalkylethyl, alkenyl, haloalkenyl, aliphatic alcohol, hydroxyl,morpholinoethyl, alkylmorpholinomethyl, alkylpiperidinylmethyl or atetrahydropyranylmethyl group, whether or not further substituted on the butaldehyde groupto any extent.

(6) Cumylindolecarboxamides: Any compound containing aN-(2-phenylpropane-2-yl)-1H-indole-3-carboxamide structure, with or without substitutionin the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkoxy, aryl, aryl halide, alkylarylhalide,cycloalkymethyl, cycloalkylethyl, alkenyl, haloalkenyl, aliphatic alcohol, hydroxyl,morpholinoethyl, alkylmorpholinomethyl, alkylpiperidinylmethyl or atetrahydropyranylmethyl group, whether or not further substituted on the phenyl group to anyextent.

(7) Cyclohexylphenols: any compound containing a 2-(3-hydroxycyclohexyl)phenolstructure, whether or not substituted in the cyclohexyl ring to any extent or the phenyl ringto any extent.

(8) Cyclopropanoylindoles: any compound containing a 3-(cyclopropanoyl)indolestructure, whether or not substituted in the indole ring to any extent or the cyclopropyl ringto any extent.

(9) (1-(5-fluoropentyl)-1H-benzimidazol-2-yl)(naphthalen-1-yl) methanone

(10) 1-(5-fluoropentyl)N-naphthalen-1-yl)-1H-pyrrolo[3,2-c]pyridine-3-

carboxamide

(11) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-B]

pyridine-3-carboxamide [5FCUMYL-P7AICA]

(12) Hexahydrodibenzopyrans whether or not substituted in the tricyclic ring systemexcept where contained in cannabis or cannabis resin.

(13) 1-methoxy-3,3-dimethyl-1-oxobutanyl-2yl-(1-cyclohexylmethyl)-1H-indazole-3-carboxylate

(14) (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl) methanone

(15) naphthalen-1-yl(9-(5-fluoropentyl)-9H-carbazol-3-yl)methanone

(16) naphthalen-1-yl(9-pentyl-9H-carbazol-3-yl)methanone

(17) Naphthoylindoles: any compound containing a 3-(1-naphthoyl)indole structure,whether or not substituted in the indole ring to any extent or the naphthyl ring to any extent.

(18) Naphthoylpyrroles: any compound containing a 3-(1-naphthoyl)pyrrolestructure, whether or not substituted in the pyrrole ring to any extent or the naphthyl ring toany extent.

(19) Naphthylamidoindoles: any compound containing a N-(naphthyl)-1H-indole-3-carboxamide structure, whether or not further substituted in the indole ring to anyextent or whether or not substituted in the naphthyl ring to any extent.

(20) Naphthylindolecarboxylates: Any compound containing anaphthyl-1H-indole-3-carboxylate structure, whether or not further substituted in the indolering or the naphthyl ring to any extent.

(21) Naphthylmethylindenes: any compound containing a 1-(1-naphthylmethyl)indene structure, whether or not substituted in the indene ring to any extentor the naphthyl ring to any extent.

(22) Naphthylmethylindoles: any compound containing a 1-H-indol-3-yl-(1-naphthyl)methane structure, whether or not substituted in the indole ring to any extent or thenaphthyl ring to any extent.

(23) N-fenchyl-1-[2-(morpholin-4-yl)ethyl]-7-methoxyindole-3-carboxamide

(24) Phenylacetylindoles: any compound containing a 3-phenylacetylindolestructure, whether or not substituted in the indole ring to any extent or the phenyl ring to anyextent.

(25) Phenylindolecarboxamides: Any compound containing aN-phenyl-1H-indole-3-carboxamide structure, whether or not further substituted in the indolering or the phenyl ring to any extent.

(26) Phenylpropionaldehydeamidoindoles: Any compound containing aN-(1-oxo-3-phenylpropan-2yl)-1H-indole-3-carboxamide structure, with or withoutsubstitution in the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkoxy, aryl, aryl halide,alkylarylhalide, cycloalklymethyl, cycloalkylethyl, alkenyl, haloalkenyl, aliphatic alcohol,hydroxyl, morpholinoethyl, alkylmorpholinomethyl, alkylpiperidinylmethyl or atetrahydropyranylmethyl group, whether or not further substituted on thephenylpropionaldehyde group to any extent.

(27) Quinolinylindolecarboxamides: Any compound containing aN-quinolinyl-1H-indole-3-carboxamide or N-isoquinolinyl-1H-indole-3-carboxamidestructure, whether or not further substituted in the indole, quinoline or the isoquinoline ringto any extent.

(28) Quinolinylindolecarboxylates: any compound containing aquinolin-8-yl-1H-indole-3-carboxylate or isoquinolin-8-yl-1H-indole-3-carboxylate structure, whether or not further substituted in the indole, quinloline, or isoquinoline ringto any extent.

(29) Tetrahydrodibenzopyrans whether or not substituted in the tricyclic ring systemexcept where contained in cannabis or cannabis resin.

NOTE: Subsection (G) eff. when the United States Drug EnforcementAdministration classifies Mitragynine as a Schedule I Controlled DangerousSubstance. See Acts 2019, No. 231.

G. Miscellaneous. Unless specifically excepted or contained within apharmaceutical product approved by the United States Food and Drug Administration, orunless listed in another schedule, any material, compound, mixture, or preparation whichcontains any quantity of the following substances including its salts, isomers, or salts ofisomers, whenever the existence of such salts, isomers, or salts of isomers is possible withinthe specific chemical designation:

(1) Mitragynine

(2) 7-Hydroxy-mitragynine

SCHEDULE II

A. Substances of vegetable origin or chemical synthesis. Unless specificallyexcepted or unless listed in another schedule, any of the following substances whetherproduced directly or indirectly by extraction from substances of vegetable origin, orindependently by means of chemical synthesis, or by a combination of extraction andchemical synthesis:

(1) Opium and opiate, and any salt, compound, derivative, or preparation of opiumor opiate, excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine,naldemedine, nalmefene, naloxegol, naloxone, 6β-naltrexol, and samidorphan, and theirrespective salts, but including the following:

(a) Raw opium

(b) Opium extracts

(d) Powdered opium

(e) Granulated opium

(f) Tincture of opium

(g) Repealed by Acts 1999, No. 755, §2.

(h) Codeine

(i) Dihydroetorphine

(j) Ethylmorphine

(k) Etorphine hydrochloride

(l) Hydrocodone

(m) Hydromorphone

(n) Metopon

(o) Morphine

(p) Oxycodone

(q) Oxymorphone

(r) Thebaine

(s) Oripavine

(2) Any salt, compound, isomer, derivative, or preparation thereof which ischemically equivalent or identical with any of the substances referred to in Paragraph (1),except that these substances shall not include the isoquinoline alkaloids of opium.

(3) Opium poppy and poppy straw.

(4) Coca leaves, and any salt, compound, derivative, or preparation of coca leaves(including cocaine ecgonine and their salts, isomers, derivatives and salts of isomers andderivatives), and any salt, compound, derivative, or preparation thereof which is chemicallyequivalent or identical with any of these substances, except that the substances shall notinclude:

(a) Decocainized coca leaves or extraction of coca leaves, which extractions do notcontain cocaine or ecgonine.

(b) Ioflupane, with and without radioisotopes.

(5) Repealed by Acts 2001, No. 282, §2.

(6) Concentrate of poppy straw (the crude extract of poppy straw in either liquid,solid, or powder form which contains the phenanthrene alkaloids of the opium poppy).

B. Opiates. Unless specifically excepted or unless listed in another schedule, any ofthe following opiates, including its isomers, esters, ethers, salts, and salts of isomers, esters,ethers, and salts is possible within the specific chemical designation, dextrorphan andlevopropoxyphene excepted:

(1) Alfentanil

(2) Alphaprodine

(3) Anileridine

(4) Bezitramide

(5) Bulk Dextropropoxyphene (non-dosage forms)

(6) Carfentanil

(7) Dihydrocodeine

(8) Diphenoxylate

(9) Fentanyl

(10) Isomethadone

(11) Levo-alphacetylmethadol

(12) Levomethorphan

(13) Levorphanol

(14) Metazocine

(15) Methadone

(16) Methadone-intermediate, 4-cyano-2-dimethylamino-4,4-diphenylbutane

(17) Moramide-intermediate, 2-methyl-3-morpholino-1,1-diphenylpropane-

carboxylic acid

(18) Oliceridine

(19) Pethidine (meperidine)

(20) Pethidine-intermediate-A, 4-cyano-1-methyl-4-phenyl-piperidine

(21) Pethidine-intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate

(22) Pethidine-intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid

(23) Phenazocine

(24) Piminodine

(25) Racemethorphan

(26) Racemorphan

(27) Remifentanil

(28) Sufentanil

(29) Tapentadol

(30) Thiafentanil

C. Stimulants. Unless specifically excepted or unless listed in another schedule, anymaterial, compound, mixture, or preparation which contains any quantity of the followingsubstances having a stimulant effect on the central nervous system:

(1) Amphetamine, its salts, optical isomers, and salts of its optical isomers

(2) Methamphetamine, its salts, isomers, and salts of its isomers

(3) Phenmetrazine and its salts

(4) Methylphenidate

(5), (6) Repealed by Acts 1999, No. 755, §2.

(7) Lisdexamfetamine, its salts, isomers, and salts of its isomers

D.(1) Depressants. Unless specifically excepted or unless listed in another schedule,any material, compound, mixture, or preparation which contains any quantity of thefollowing substances having a depressant effect on the central nervous system, including itssalts, isomers, or salts of isomers, whenever the existence of such salts, isomers, and saltsof isomers is possible within the specific chemical designation:

(a) Amobarbital

(b) Carisoprodol

(d) Pentobarbital

(e) Phencyclidine

(f) Secobarbital

(2) A wholesale drug distributor licensed by the Louisiana Board of Pharmacy andregistered with the United States Drug Enforcement Administration shall be exempt from thestorage, reporting, record keeping, and physical security requirements for any material,mixture, compound, or preparation which contains any quantity of Carisoprodol.

E. Immediate precursors.

(1) Unless specifically excepted or unless listed in another schedule, any material,compound, mixture, or preparation which contains any quantity of the following substances:

(a) Immediate precursors to amphetamine and methamphetamine: phenylacetone.

(b) Immediate precursors to phencyclidine (PCP):

(i) 1-phenylcyclohexylamine;

(ii) 1-piperidinocyclohexanecarbonitrile (PCC).

(i) 4-anilino-N-phenethyl-4-piperidine (ANPP)

(ii) Norfentanyl (N-phenyl-N-(piperidin-4-yl)propionamide)

(2) For purposes of this Subsection, possession of immediate precursors sufficientfor the manufacture of phenylacetone, piperidine, or cyclohexanone shall be deemed to bepossession of such a derivative substance.

F. Hallucinogenic substances:

(1) Nabilone

(2) Dronabinol [delta-9-trans tetrahydrocannabinol] in an oral solution in a drugproduct approved for marketing by the United States Food and Drug Administration.

NOTE: Subsection (G) eff. when the United States Drug EnforcementAdministration classifies Mitragynine as a Schedule II Controlled DangerousSubstance. See Acts 2019, No. 231.

(1) Mitragynine

(2) 7-Hydroxy-mitragynine

SCHEDULE III

A. Stimulants. Unless specifically excepted or unless listed in another schedule, anymaterial, compound, mixture, or preparation which contains any quantity of the followingsubstances having a stimulant effect on the central nervous system:

(1) Benzphetamine

(2) Chlorphentermine

(3) Clortermine

(4) Repealed by Acts 1982, No. 92, §2.

(5) Repealed by Acts 2008, No. 67, §2.

(6) Phendimetrazine

B. Depressants. Unless specifically excepted or unless listed in another schedule,any material, compound, mixture, or preparation which contains any quantity of thefollowing substances having a depressant effect on the central nervous system:

(1) Any compound, mixture, or preparation containing:

(a) Amobarbital

(b) Secobarbital

(2) Any suppository dosage form containing:

(a) Amobarbital

(b) Secobarbital

(c) Pentobarbital or any salt of any of these drugs and approved by the federal Foodand Drug Administration for marketing only as a suppository.

(3) Any substance which contains any quantity of a derivative of barbituric acid, orany salt thereof, but not including butalbital when in combination with at least three hundredtwenty-five milligrams of acetaminophen per dosage unit.

(4) Chlorhexadol

(5) Embutramide

(6) Any drug product containing gamma hydroxybutyric acid, including its salts,isomers, and salts of isomers, which has been approved by the federal Food and DrugAdministration.

(7) Ketamine, its salts, isomers, and salts of isomers

(8) Lysergic acid

(9) Lysergic acid amide

(10) Methyprylon

(11) Sulfondiethylmethane

(12) Sulfonethylmethane

(13) Sulfonmethane

(14) Tiletamine and zolazepam or any salt thereof

(15) Perampanel

C. Nalorphine

D. Limited narcotic drugs. Unless specifically excepted or unless listed in anotherschedule:

(1) Any material, compound, mixture, or preparation containing limited quantitiesof any of the following narcotic drugs, or any salts thereof:

(a) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90milligrams per dosage unit with an equal or greater quantity of an isoquinoline alkaloid ofopium.

(b) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognizedtherapeutic amounts.

(c), (d) Repealed by Acts 2015, No. 189, §2, eff. June 23, 2015.

(e) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients inrecognized therapeutic amounts.

(f) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not morethan 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients inrecognized therapeutic amounts.

(g) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, ornot more than 25 milligrams per dosage unit, with one or more active, nonnarcoticingredients in recognized therapeutic amounts.

(h) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams,with one or more active nonnarcotic ingredients in recognized therapeutic amounts.

(2) Any material, compound, mixture, or preparation containing any of the followingnarcotic drugs or their salts:

(a) Buprenorphine

E. Anabolic steroids and muscle building substances. Unless specifically exceptedor unless listed in another schedule, any material, compound, mixture, or preparation,containing any quantity of the following substances, including its salts, esters, ethers,isomers, and salts of isomers whenever the existence of such salts, esters, ethers, isomers,and salts of isomers is possible within the specific chemical designation. The term "anabolicsteroid" means any drug or hormonal substance, chemically and pharmacologically relatedto testosterone, other than estrogens, progestins, corticosteroids, and dehydroepiandrosteronethat promote muscle growth and include the following:

(1) 3β,17-dihydroxy-5a-androstane

(2) 3α,17β-dihydroxy-5a-androstane

(3) 5α-androstan-3,17-dione

(4) 3β,17β-dihydroxy-5α-androst-1-ene

(5) 3α,17β-dihydroxy-5α-androst-1-ene

(6) 4-androstenediol

(7) 5-androstenediol

(8) 1-androstenedione

(9) 4-androstenedione

(10) 5-androstenedione

(11) Bolasterone

(12) Boldenone

(12.1) Boldione

(13) Calusterone

(14) Clostebol

(15) Dehydrochloromethyltestosterone

(15.1) Desoxymethyltestosterone

(16) Δ1-dihydrotestosterone

(17) 4-dihydrotestosterone

(18) Drostanolone

(19) Ethylestrenol

(20) Fluoxymesterone

(21) Formebolone

(22) Furazebol

(23) 13β-ethyl-17α-hydroxygon-4-en-3-one

(24) 4-hydroxytestosterone

(25) 4-hydroxy-19-nortestosterone

(26) Mestanolone

(27) Mesterolone

(28) Methandienone

(29) Methandriol

(29.1) Methasterone (2,17α-dimethyl-5α-androstan-17α-ol-3-one)

(30) Methenolone

(31) 17α-methyl-3β,17β-dihydroxy-5a-androstane

(32) 17α-methyl-3α,17β-dihydroxy-5a-androstane

(33) 17α-methyl-3β,17β-dihydroxyandrost-4-ene

(34) 17α-methyl-4-hydroxynandrolone

(35) Methyldienolone

(36) Methyltrienolone

(37) Methyltestosterone

(38) Mibolerone

(39) 17α-methyl-Δ1-dihydrotestosterone

(40) Nandrolone

(41) 3β,17β-dihydroxyestr-4-ene

(42) 3α,17β-dihydroxyestr-4-ene

(43) 3β,17β-dihydroxyestr-5-ene

(44) 3α,17β-dihydroxyestr-5-ene

(44.1) 19-nor-4, 9(10)-androstadienedione

(45) 19-nor-4-androstenedione

(46) 19-nor-5-androstenedione

(47) Norbolethone

(48) Norclostebol

(49) Norethandrolone

(50) Normethandrolone

(51) Oxandrolone

(52) Oxymesterone

(53) Oxymetholone

(53.1) Prostanozol (17α-hydroxy-5α-androstano[3,2-c]pyrazole)

(54) Stanozolol

(55) Stenbolone

(56) Testolactone

(57) Testosterone

(58) Tetrahydrogestrinone

(59) Trenbolone

F.(1) Except as provided in Paragraph (2) of this Schedule, the term anabolic steroiddoes not include a substance listed in Subsection E of this Section but which is expresslyintended for administration to livestock or other nonhuman species and which has beenapproved by the secretary for such an administration.

(2) If any person prescribes, dispenses, or distributes such steroid for human use,such person shall be considered to have prescribed, dispensed, or distributed an anabolicsteroid within the meaning of Subsection E of this Schedule.

(3) A physician, dentist, or veterinarian shall not prescribe, dispense, deliver, oradminister an anabolic steroid for human use or cause an anabolic steroid to be administeredunder his direction or supervision for human use except for a valid medical purpose andwhen required by demonstrable generally accepted medical indications. Bodybuilding,muscle enhancement, or increasing muscle bulk or strength through the use of an anabolicsteroid by a person who is in good health is hereby declared not a valid medical purpose.

G. Substances of vegetable origin or chemical synthesis. Unless specificallyexcepted or unless listed in another schedule, any of the following substances whetherproduced directly or indirectly by extraction from substances of vegetable origin, orindependently by means of chemical synthesis, or by a combination of extraction andchemical synthesis:

(1) Synthetic Dronabinol [delta-9-(trans) tetrahydrocannabinol] in sesame oil andencapsulated in a soft gelatin capsule in a United States Food and Drug Administrationapproved product.

NOTE: Subsection (H) eff. when the United States Drug EnforcementAdministration classifies Mitragynine as a Schedule III Controlled DangerousSubstance. See Acts 2019, No. 231.

H. Miscellaneous. Unless specifically excepted or contained within apharmaceutical product approved by the United States Food and Drug Administration, orunless listed in another schedule, any material, compound, mixture, or preparation whichcontains any quantity of the following substances including its salts, isomers, or salts ofisomers, whenever the existence of such salts, isomers, or salts of isomers is possible withinthe specific chemical designation:

(1) Mitragynine

(2) 7-Hydroxy-mitragynine

SCHEDULE IV

A. Narcotic drugs. Unless specifically excepted or unless listed in another schedule,any material, compound, mixture, or preparation containing any of the following narcoticdrugs, or their salts, in limited quantities, as set forth below:

(1) Not more than 1 milligram of difenoxin and not less than 25 micrograms ofatropine sulfate per dosage unit.

(2) Dextropropoxyphene.

(3) Tramadol (2-[(dimethylamino)methyl]-1-(3-methoxyphenyl) cyclohexanol), itssalts, isomers, and salts of its isomers.

B. Depressants. Unless specifically excepted or unless listed in another schedule,any material, compound, mixture, or preparation containing any quantity of the followingsubstances, including its salts, isomers, and salts of isomers, whenever the existence of suchsalts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Alfaxalone

(2) Alprazolam

(3) Barbital

(4) Brexanolone

(5) Bromazepam

(6) Camazepam

(7) Chloral betaine

(8) Choral hydrate

(9) Chlordiazepoxide, but not including chlordiazepoxide hydrochloride incombination with clidinium bromide, or chlordiazepoxide and water-soluble esterifiedestrogens.

(10) Clobazam

(11) Clonazepam

(12) Clorazepate

(13) Clotiazepam

(14) Cloxazolam

(15) Delorazepam

(16) Diazepam

(17) Dichloralphenazone

(18) Estazolam

(19) Ethchlorvynol

(20) Ethinamate

(21) Ethyl loflazepate

(22) Fludiazepam

(23) Flunitrazepam

(24) Flurazepam

(25) Fospropofol

(26) Halazepam

(27) Haloxazolam

(28) Ketazolam

(29) Lemborexant

(30) Loprazolam

(31) Lorazepam

(32) Lormetazepam

(33) Mebutamate

(34) Medazepam

(35) Meprobamate

(36) Methohexital

(37) Methylphenobarbital (mephobarbital)

(38) Midazolam

(39) Nimetazepam

(40) Nitrazepam

(41) Nordiazepam

(42) Oxazepam

(43) Oxazolam

(44) Paraldehyde

(45) Petrichloral

(46) Phenobarbital

(47) Pinazepam

(48) Prazepam

(49) Quazepam

(50) Remimazolam

(51) Suvorexant

(52) Temazepam

(53) Tretrazepam

(54) Triazolam

(55) Zaleplon

(56) Zolpidem

(57) Zopiclone

C. Fenfluramine. Any material, compound, mixture, or preparation which containsany quantity of the following substances, including its salts, isomers (whether optical,position, or geometric), and salts of isomers, whenever the existence of such salts, isomers,and salts of isomers including Fenfluramine is possible.

D. Stimulants. Unless specifically excepted or unless listed in another schedule, anymaterial, compound, mixture, or preparation which contains any quantity of the followingsubstances, including its salts, isomers, and salts of isomers:

(1) Cathine (norpseudoephedrine)

(2) Diethylpropion

(3) Fencamfamin

(4) Fenproporex

(5) Lorcaserin

(6) Mazindol

(7) Mefenorex

(8) Modafinil

(9) Pemoline (including organometallic complexes and chelates thereof)

(10) Phentermine

(11) Pipradrol

(12) Serdexmethylphenidate

(13) Sibutramine

(14) Solriamfetol (2-amino-3-phenylpropyl carbamate; benzenepropanol, beta-amino-,carbamate (ester))

(15) SPA [(-)-1-dimethylamino-1,2-diphenylethane]

E. Other substances. Unless specifically excepted or unless listed in anotherschedule, any material, compound, mixture, or preparation which contains any quantity ofthe following substances, including its salts:

(1) Pentazocine

(2) Butorphanol (including its optical isomers)

(3) Eluxadoline (5-[[[2-amino-3-[(4-aminocarbonyl)-2,6-dimethylphe

nyl]-1-oxopropyl][1-(4-phenyl-1H-imidazol-2-yl)theyl]amino]methyl]-2-methoxybenzoicacid) (including its optical isomers) and its salts, isomers, and salts of isomers.

NOTE: Subsection (F) eff. when the United States Drug EnforcementAdministration classifies Mitragynine as a Schedule IV Controlled DangerousSubstance. See Acts 2019, No. 231.

F. Miscellaneous. Unless specifically excepted or contained within apharmaceutical product approved by the United States Food and Drug Administration, orunless listed in another schedule, any material, compound, mixture, or preparation whichcontains any quantity of the following substances including its salts, isomers, or salts ofisomers, whenever the existence of such salts, isomers, or salts of isomers is possible withinthe specific chemical designation:

(1) Mitragynine

(2) 7-Hydroxy-mitragynine

SCHEDULE V

A. Narcotic drugs containing nonnarcotic active medicinal ingredients. Anycompound, mixture, or preparation containing any of the following limited quantities ofnarcotic drugs or salts thereof, which shall include one or more nonnarcotic active medicinalingredients in sufficient proportion to confer upon the compound, mixture, or preparationvaluable medicinal qualities other than those possessed by the narcotic drug alone:

(1) Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams.

(2) Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100grams.

(3) Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100grams.

(4) Not more than 2.5 milligrams of diphenoxylate and not less than 25 microgramsof atropine sulphate per dosage unit.

(5) Not more than 100 milligrams of opium per 100 milliliters or per 100 grams.

(6) Not more than 0.5 milligrams of difenoxin and not less than 25 micrograms ofatropine sulfate per dosage unit.

B. Narcotic drugs. Unless specifically excepted or unless listed in another schedule,any material, compound, mixture, or preparation containing any of the following narcoticdrugs and their salts, as set forth below:

(1) Repealed by Acts 2006, No. 54, §2.

C. Stimulants. Unless specifically exempted or excluded or unless listed in anotherschedule, any material, compound, mixture, or preparation which contains any quantity ofthe following substances having a stimulant effect on the central nervous system, includingits salts, isomers, and salts of isomers:

(1) Pyrovalerone

D. Depressants. Unless specifically exempted or excluded or unless listed in anotherschedule, any material, compound, mixture, or preparation which contains any quantity ofthe following substances having a depressant effect on the central nervous system, includingits salts:

(1) Brivaracetam (2-[2-oxo-4-propylpyrrolidin-1-yl]butanamide), also referred to asBRV; UCB-34714; Briviact.

(2) Cenobamate (1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethylcarbamate)

(3) Ezogabine

(4) Lacosamide

(5) Lasmiditan (2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-carbonyl) pyridine-2-yl-benzamide)

(6) Pregbalin

E.(1) Ephedrine, pseudoephedrine, phenylpropanolamine. Unless listed in anotherschedule, any material, compound, mixture, or preparation containing any detectable quantityof ephedrine, pseudoephedrine, or phenylpropanolamine, their salts or optical isomers, orsalts of optical isomers.

(2)(a) Nonprescription products containing ephedrine, pseudoephedrine, orphenylpropanolamine shall not be sold or distributed in a quantity greater than nine gramsof ephedrine base, pseudoephedrine base, or phenylpropanolamine base to the samepurchaser within any thirty-day period.

(b) Notwithstanding the prescription requirements for Schedule V controlleddangerous substances as provided for in R.S. 40:978(C), nonprescription products containingephedrine, pseudoephedrine, or phenylpropanolamine may be dispensed without aprescription.

(3)(a) No person shall purchase, receive, or otherwise acquire more than nine gramsof ephedrine base, pseudoephedrine base, or phenylpropanolamine base within any thirty-dayperiod.

(b) This limit shall not apply to any quantity of such product, mixture, or preparationdispensed pursuant to a valid prescription written by a licensed healthcare professionalhaving prescriptive authority.

(4) Wholesale drug distributors licensed by the Louisiana Board of Drug and DeviceDistributors and registered with the United States Drug Enforcement Administration shallbe exempt from the storage, reporting, record keeping, and physical security requirementsfor controlled dangerous substances for nonprescription products containing ephedrine,pseudoephedrine, and phenylpropanolamine which are not listed in another schedule.

(5) Except for sales log requirements and the transmittal of transaction informationto the central computer monitoring system authorized by the provisions of Part X-F ofChapter 4 of Title 40 of the Louisiana Revised Statutes of 1950, pharmacies and pharmacistslicensed by the Louisiana Board of Pharmacy and registered with the United States DrugEnforcement Administration shall be exempt from the storage, reporting, record keeping, andphysical security requirements for controlled dangerous substances for nonprescriptionproducts containing ephedrine, pseudoephedrine, or phenylpropanolamine which are notlisted in another schedule.

(6) The transaction information provided for in R.S. 40:1049.3 for the purchase ofa nonprescription product containing ephedrine, pseudoephedrine, or phenylpropanolamineshall constitute an "order from a practitioner" as provided for in R.S. 40:970(C). Possessionof a nonprescription product containing ephedrine, pseudoephedrine, orphenylpropanolamine pursuant to a valid transaction as provided for in R.S. 40:1049.3 shallbe a defense for a violation of R.S. 40:970(C).

F. Repealed by Acts 2021, No. 101, §2.

NOTE: Subsection (G) eff. when the United States Drug EnforcementAdministration classifies Mitragynine as a Schedule V Controlled DangerousSubstance. See Acts 2019, No. 231.

(1) Mitragynine

(2) 7-Hydroxy-mitragynine

Amended by Acts 1991, No. 513, §§1, 3; Acts 1991, No. 842, §1, eff. July 23, 1991;Acts 1993, No. 156, §§1, 2; Acts 1993, No. 288, §1; Acts 1993, No. 616, §1; Acts 1997, No.398, §1; Acts 1998, 1st Ex. Sess., No. 129, §1; Acts 1999, No. 582, §1; Acts 1999, No. 755,§§1 and 2; Acts 2000, 1st Ex. Sess., No. 13, §1, eff. April 13, 2000; Acts 2001, No. 282, §§1and 2; Acts 2001, No. 1036, §1; Acts 2004, No. 702, §1; Acts 2006, No. 54, §§1, 2; Acts2006, No. 56, §1; Acts 2008, No. 67, §§1, 2; Acts 2009, No. 153, §1; Acts 2009, No. 165,§1; Acts 2009, No. 314, §1; Acts 2010, No. 565, §1; Acts 2010, No. 810, §§1, 2; Acts 2010,No. 866, §1; Acts 2011, No. 420, §§1, 2, eff. July 15, 2011; Acts 2012, No. 315, §1; Acts2012, No. 345, §1, eff. May 28, 2012; Acts 2013, No. 7, §1; Acts 2013, No. 8, §1; Acts 2014,No. 40, §1; Acts 2014, No. 43, §1; Acts 2014, No. 397, §§1, 2; Acts 2015, No. 189, §§1, 2,eff. June 23, 2015; Acts 2015, No. 373, §1, eff. July 1, 2015; Acts 2016, No. 62, §1; Acts2017, No. 100, §1; Acts 2018, No. 119, §1; Acts 2018, No. 206, §4; Acts 2019, No. 231,§§1, 2, 3, 4, 5; Acts 2019, No. 354, §1; Acts 2020, No. 10, §1; Acts 2021, No. 101, §§1, 2;Acts 2022, No. 46, §1.

*NOTE: Asterisks in Schedule I(A) and (B) indicate substances which arenarcotics.